匹维溴胺联合曲美布丁痛泻宁治疗肠易激综合征的疗效观察  

Observation on the Efficacy of Pivobromide Combined with Trimebutine Tongxiening in the Treatment of Irritable Bowel Syndrome

作　　者：朱瑞刚 ZHU Rui-gang(Department of Gastroenterology,Henan Shengde Hospital,Xinyang,Henan,464000,China)

机构地区：[1]河南圣德医院消化内科,河南信阳464000

出　　处：《黑龙江医学》2020年第4期523-525,共3页Heilongjiang Medical Journal

摘　　要：目的探讨匹维溴胺联合曲美布丁痛泻宁治疗肠易激综合征(Irritablebowelsyndrome,IBS)的治疗效果。方法选择于2018年3月-2019年9月间河南圣德医院收治的80例IBS患者,随机分为两组,每组各40例。对照组予以常规治疗、曲美布丁痛泻宁联合双歧四联活菌治疗,观察组予以常规治疗、匹维溴胺联合曲美布丁痛泻宁治疗。观察两组患者临床症状积分及不良反应情况。结果治疗前,两组患者症状积分对比,差异无统计学意义(P>0.05);治疗3 d后,观察组患者症候积分明显低于对照组,且两组总积分均明显下降,差异有统计学意义(P<0.05);治疗后,两组患者不良反应对比,差异无统计学意义(P>0.05)。结论匹维溴胺联合曲美布丁痛泻宁治疗IBS的效果显著,可有效改善患者临床症状,提高肠运动功能,且安全性较高。Objective To investigate the therapeutic effect of pivobromide combined with trimebutine Tongxiening on Irritable bowel syndrome(IBS). Methods 80 patients with IBS admitted to the hospital from March, 2018 to September, 2019 were randomly divided into two groups, with 40 cases in each group. The control group was treated with routine treatment, trimebutine Tongxiening combined with bifid tetrad viable bacteria, while the observation group was treated with routine treatment, pivobromide combined with trimebutine tongxiening. The clinical symptom scores and adverse reactions of the two groups were observed. Results Before treatment, there was no significant difference in symptom score between the two groups(P>0.05). After 3 days of treatment,the symptom score of the observation group was significantly lower than that of the control group, and the total score of the two groups decreased significantly(P<0.05). After treatment, there was no significant difference in adverse reactions between the two groups(P>0.05). Conclusion Pivecromide combined with trimebutine and tongxieling has a significant effect on irritable bowel syndrome, can effectively improve the clinical symptoms, improve the intestinal motor function, and has a high safety.

关 键 词：肠易激综合征 匹维溴胺 曲美布丁痛泻宁 

分 类 号：R574.4[医药卫生—消化系统]